Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Phase 2 Completed 59 enrolled Novartis Pharmaceuticals

NaSingle-groupOpen-label

Summary

To provide medical follow-up to patients exposed to BGG492 for more than 28 days in study CBGG492A2207 (NCT 01147003) and/or CBGG492A2212 (NCT 01338805).

Timeline

Start: 2014-08
Primary completion: 2015-09
Completion: 2015-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	selurampanel	Small molecule	—	—

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Summary

Timeline

Drugs

Indications